PMC:7696151 / 23801-23968 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"712","span":{"begin":39,"end":59},"obj":"Chemical"},{"id":"713","span":{"begin":90,"end":99},"obj":"Chemical"},{"id":"714","span":{"begin":135,"end":138},"obj":"Chemical"}],"attributes":[{"id":"A713","pred":"tao:has_database_id","subj":"713","obj":"MESH:D012254"},{"id":"A714","pred":"tao:has_database_id","subj":"714","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"C) consisted of 160 µg of subcutaneous pegylated interferon and 1000–12000 mg/day of oral ribavirin, and the group treated with 200 mg HCQ plus SOC. At the end of the "}